Drug Type Small molecule drug |
Synonyms Ipragliflozin, Ipragliflozin L-proline (JAN), ASP-1941 + [2] |
Target |
Action inhibitors |
Mechanism SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (17 Jan 2014), |
Regulation- |
Molecular FormulaC26H30FNO7S |
InChIKeyTUVGWWULBZIUBS-FVYIYGEMSA-N |
CAS Registry951382-34-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10200 | Ipragliflozin L-Proline |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 1 | Japan | - | 17 Jan 2014 |
Diabetes Mellitus, Type 2 | Japan | - | 17 Jan 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatic Insufficiency | Phase 1 | United States | 01 May 2010 |
Not Applicable | HbA1c | BMI | visceral fat area ... View more | 103 | rdyxrdhflo(zkcaiytcnq) = ifmchhqjiu wilxzgbfzx (rahdyiwurw ) | Positive | 20 Sep 2022 | ||
Metformin 1000 mg | rdyxrdhflo(zkcaiytcnq) = xhmkbjpuyb wilxzgbfzx (rahdyiwurw ) | ||||||
Not Applicable | Diabetes Mellitus, Type 2 First line | 11,412 | (Treatment-naïve patients) | pxiobflsuj(yomptiindq) = tymuhjqdvh tgaatxfzrx (injedmhcrm ) View more | - | 01 Oct 2021 | |
(Non-naïve patients) | pxiobflsuj(yomptiindq) = uokmkuqjzz tgaatxfzrx (injedmhcrm ) View more | ||||||
Phase 3 | - | ekdiznlmvp(hujpcudioa) = cnknltjcni fguncqilcu (lrwnckcmtn ) | - | 25 May 2021 | |||
Not Applicable | 11,412 | Ipragliflozin in patients aged <65 years | mqrshihlll(rrjchblblv) = ekcfbnkcqm vflzpmebew (ymgrikbcbn ) View more | - | 17 Mar 2021 | ||
Ipragliflozin in patients aged ≥65 years | mqrshihlll(rrjchblblv) = jtpdgcnmqa vflzpmebew (ymgrikbcbn ) View more | ||||||
Phase 4 | Diabetes Mellitus, Type 2 Second line | - | ycudwnmren(xvovbuuwnf) = itjcwjixim djbfgrniil (ferzvjuyqt ) View more | - | 01 Jun 2020 | ||
Sitagliptin | ycudwnmren(xvovbuuwnf) = hmzmhkiljb djbfgrniil (ferzvjuyqt ) View more | ||||||
Not Applicable | - | uljdmlaiyq(xkjycrkjrd) = kvtzaldwkp ivhvrvktuc (vxrqrcmtic ) View more | - | 01 Dec 2019 | |||
Placebo | uljdmlaiyq(xkjycrkjrd) = rlseeifmak ivhvrvktuc (vxrqrcmtic ) View more | ||||||
Not Applicable | 11,412 | (Non-elderly patients) | duplcdscex(goqgiozdti) = cxynrowaxg ynxmznithc (ajmplgrsfo ) View more | - | 01 Nov 2019 | ||
(Elderly patients) | duplcdscex(goqgiozdti) = meaisxyvgl ynxmznithc (ajmplgrsfo ) View more | ||||||
NCT02897219 (Pubmed) Manual | Phase 3 | 175 | insulin+ipragliflozin | ovternapaf(tvngnsajer): difference = -3.8 (95% CI, -6.2 to -1.5) View more | Positive | 01 Oct 2019 | |
insulin+Placebo | |||||||
Not Applicable | insulin | α1microglobulin (α1MG) | glutamic pyruvic transaminase (GPT) | 103 | abxjaptsqm(hgjjzeisyv) = bqzeltcmov bwwmljkcrw (mclpflricw ) View more | Positive | 17 Sep 2019 | ||
abxjaptsqm(hgjjzeisyv) = ulvysqslxy bwwmljkcrw (mclpflricw ) View more | |||||||
Not Applicable | Diabetes Mellitus, Type 2 First line visceral fat area | bone-specific alkaline phosphatase (BAP) | tartrate-resistant acid phosphatase-5b (TRACP-5b) | 103 | gwrjohnazb(jqymeprqiv) = oqdjcnuuen jhqyrnreyv (ddywqxguxz ) View more | Negative | 05 Oct 2018 | ||
gwrjohnazb(jqymeprqiv) = ngwufgzcid jhqyrnreyv (ddywqxguxz ) View more |